Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition

Molecules

Volumn 18, Issue 12, 2013, Pages 15398-15411

  Hou, Duen Ren ^a   Huang, Ann Chi ^a   Shiau, Chung Wai ^b   Wang, Chun Yi ^a   Yu, Hui Chuan ^c   Chen, Kuen Feng ^c  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bortezomib; CIP2A

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; BORONIC ACID DERIVATIVE; BORTEZOMIB; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENETICS; HUMAN; IC 50; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890904236     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules181215398     Document Type: Article

References (12)

1. Junttila, M.R.; Puustinen, P.; Niemela, M.; Ahola, R.; Arnold, H.; Bottzauw, T.; Ala-aho, R.; Nielsen, C.; Ivaska, J.; Taya, Y.; et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130, 51-62.
2. Sablina, A.A.; Hahn, W.C. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev. 2008, 27, 137-146.
3. Khanna, A.; Bockelman, C.; Hemmes, A.; Junttila, M.R.; Wiksten, J.P.; Lundin, M.; Junnila, S.; Murphy, D.J.; Evan, G.I.; Haglund, C.; et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl. Cancer Inst. 2009, 101, 793-805.
4. Chen, K.F.; Liu, C.Y.; Lin, Y.C.; Yu, H.C.; Liu, T.H.; Hou, D.R.; Chen, P.J.; Cheng, A.L. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29, 6257-3266.
5. Chen, K.F.; Yeh, P.Y.; Hsu, C.; Hsu, C.H.; Lu, Y.S.; Hsieh, H.P.; Chen, P.J.; Cheng, A.L. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2009, 284, 11121-11133.
6. Tseng, L.M.; Liu, C.Y.; Chang, K.C.; Chu, P.Y.; Shiau, C.W.; Chen, K.F. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012, 14, R68.
7. Ma, L.; Wen, Z.S.; Liu, Z.; Hu, Z.; Ma, J.; Chen, X.Q.; Liu, Y.Q.; Pu, J.X.; Xiao, W.L.; Sun, H.D.; et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011, 6, e20159.
8. Nencioni, A.; Grunebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007, 21, 30-36.
9. Chen, K.F.; Yu, H.C.; Liu, C.Y.; Chen, H.J.; Chen, Y.C.; Hou, D.R.; Chen, P.J.; Cheng, A.L. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.. Mol. Cancer Ther. 2011, 10, 892-901.
10. Chen, K.F.; Yu, H.C.; Liu, T.H.; Lee, S.S.; Chen, P.J.; Cheng, A.L. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J. Hepatol. 2010, 52, 88-95.
11. Zhu, Y.; Yao, S.; Xu, B.; Ge, Z.; Cui, J.; Cheng, T.; Li, R. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors. Bioorgan. Med. Chem. 2009, 17, 6851-6861.
12. Codony-Servat, J.; Tapia, M.A.; Bosch, M.; Oliva, C.; Domingo-Domenech, J.; Mellado, B.; Rolfe, M.; Ross, J.S.; Gascon, P.; Rovira, A.; et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol. Cancer Ther. 2006, 5, 665-675